NEW YORK (GenomeWeb) – Cepheid has launched a CE marked bladder cancer test that is currently commercially available in Germany and will launch throughout Europe in the coming months.

The Xpert Bladder Cancer Monitor test runs on the firm's GeneXpert molecular diagnostics system. It has about a 94 percent negative predictive value, so could be particularly useful in more confidently ruling out bladder cancer and reducing the need for more invasive testing, Cepheid said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Nov
07
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.